David Clayton

ABBY

Jeffrey L. Cummings, Sharon Cohen, Christopher H. van Dyck et al. · Neurology · 2018 · 251 citations · Full text

Medicine, Neurology, Pharmacology +13

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease

Susanne Ostrowitzki, Tobias Bittner, Kaycee M. Sink et al. · JAMA Neurology · 2022 · 224 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

Stephen Salloway, Lee Honigberg, Michael E. Ward et al. · Alzheimer s Research & Therapy · 2018 · 152 citations · Full text

Medicine, Neurology, Pharmacology +17

Clinical multishot DW‐EPI through parallel imaging with considerations of susceptibility, motion, and noise

Stefan Skare, Rexford D. Newbould, David Clayton et al. · Magnetic Resonance in Medicine · 2007 · 150 citations · Full text

Medicine, Biomedical Engineering, Radiology +13

The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort

Pierre N. Tariot, Francisco Lopera, Jessica B. Langbaum et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2018 · 129 citations · Full text

Medicine, Neurology, Pharmacology +17